Cargando…

PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours

BACKGROUND: The extent of resistance to immune surveillance in patients with well-differentiated (Wd) (grade 1/2) small-intestinal neuroendocrine tumours (Si-NETs) is unknown. METHODS: Patients diagnosed with Wd Si-NETs (excluding appendix, which are considered to have a different biology to other m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lamarca, Angela, Nonaka, Daisuke, Breitwieser, Wolfgang, Ashton, Garry, Barriuso, Jorge, McNamara, Mairéad G., Moghadam, Sharzad, Rogan, Jane, Mansoor, Wasat, Hubner, Richard A., Clark, Christopher, Chakrabarty, Bipasha, Valle, Juan W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871087/ https://www.ncbi.nlm.nih.gov/pubmed/29599916 http://dx.doi.org/10.18632/oncotarget.24464

Ejemplares similares

Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice
por: Lamarca, Angela, et al.
Publicado: (2022)

Mixed Neuroendocrine Non-Neuroendocrine Neoplasms: A Systematic Review of a Controversial and Underestimated Diagnosis
por: Frizziero, Melissa, et al.
Publicado: (2020)

Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours
por: Chiramel, Jaseela, et al.
Publicado: (2020)

Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centres
por: Frizziero, Melissa, et al.
Publicado: (2019)

Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?
por: Frizziero, Melissa, et al.
Publicado: (2021)

The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases
por: Kapacee, Zainul-Abedin, et al.
Publicado: (2022)

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice
por: Lamarca, Angela, et al.
Publicado: (2019)

Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs)
por: Megdanova-Chipeva, Vera G., et al.
Publicado: (2020)

Endoscopic surveillance alone is feasible and safe in type I gastric neuroendocrine neoplasms less than 10 mm in diameter
por: Exarchou, Klaire, et al.
Publicado: (2022)

The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms
por: Shah, Dinakshi, et al.
Publicado: (2021)

Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis
por: McNamara, Mairéad G., et al.
Publicado: (2020)

Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes
por: Saavedra, Cristina, et al.
Publicado: (2019)

Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes
por: Taboada, Rodrigo G, et al.
Publicado: (2022)

Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma
por: Weaver, Jamie M. J., et al.
Publicado: (2023)

Future therapeutic strategies in the treatment of extrapulmonary neuroendocrine carcinoma: a review
por: Robinson, Matthew D., et al.
Publicado: (2023)

Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours
por: Lewis, Alexandra R, et al.
Publicado: (2018)

NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC)
por: Craig, Zoe, et al.
Publicado: (2020)

The Microbiome as a Potential Target for Therapeutic Manipulation in Pancreatic Cancer
por: Abdul Rahman, Rozana, et al.
Publicado: (2021)

Clinical and Pathologic Characteristics of Pulmonary Carcinoid Tumors in Central and Peripheral Locations
por: Papaxoinis, George, et al.
Publicado: (2018)

Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma
por: Foy, Victoria, et al.
Publicado: (2023)

Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review
por: Shotton, Rohan, et al.
Publicado: (2021)

NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma
por: McNamara, Mairéad G., et al.
Publicado: (2023)

Prospective observational study of prevalence, assessment and treatment of pancreatic exocrine insufficiency in patients with inoperable pancreatic malignancy (PANcreatic cancer Dietary Assessment (PanDA): a study protocol
por: Carnie, Lindsay E, et al.
Publicado: (2021)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Targeted Therapies for Perihilar Cholangiocarcinoma
por: Gray, Simon, et al.
Publicado: (2022)

The Impact of (68)Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours
por: Cuthbertson, Daniel J., et al.
Publicado: (2021)

Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer
por: Pihlak, Rille, et al.
Publicado: (2023)

Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer
por: Abraham, Marc, et al.
Publicado: (2019)

Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary Assessment—PanDA)
por: Carnie, Lindsay E., et al.
Publicado: (2023)

Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma
por: Najran, Pavan, et al.
Publicado: (2017)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
por: Lamarca, Angela, et al.
Publicado: (2020)

Diagnostic and Management Pathways for Pulmonary Carcinoid Tumours in the United Kingdom: Results from the National Lung Neuroendocrine Tumour Pathway Project
por: Mansoor, Wasat, et al.
Publicado: (2020)

Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis
por: Chiramel, Jaseela, et al.
Publicado: (2017)

Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes
por: Gray, Simon, et al.
Publicado: (2023)

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice
por: Fulton, Alexander JP, et al.
Publicado: (2019)

Fysikkpris til Fanamann
Publicado: (1981)

Petabytes til folket
Publicado: (2005)

Goldilocks and the three TILs
por: Dada, Hannah, et al.
Publicado: (2022)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
por: Arnaud, Marion, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9vq85vv98jpbdu38p7rvm5830h